secwatch.observer — SEC 8-K summary
======================================

Issuer:     OCULAR THERAPEUTIX, INC (OCUL)
CIK:        0001393434
Form:       8-K
Filed at:   2024-01-25T23:59:59+00:00
Accession:  0001104659-24-006490
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Ocular Therapeutix obtains FDA SPA modification for pivotal Phase 3 AXPAXLI wet AMD trial
--------------------------------------------------------------------------------

- FDA agreed to SPA modification for SOL trial evaluating AXPAXLI (axitinib intravitreal implant) for wet AMD.
- Modified protocol allows enrollment of treatment-naïve subjects with visual acuity of 20/80 or better at screening.
- Eligible participants must gain ≥10 ETDRS letters or achieve 20/20 vision at Day 1 after two aflibercept injections.
- Trial will evaluate a single 450 µg implant of a more soluble form of axitinib for improved drug release.
- Optimized implant designed to synchronize axitinib depletion with hydrogel bioresorption.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924006490/0001104659-24-006490-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1393434/000110465924006490/tm244106d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-24-006490

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer